This authorization is issued by the Institutional Review Board of the hospital and then comes the approval of the Ministry of Health of that country, which according to Israel News, would occur this Thursday or Friday.
Oramed is a clinical phase pharmaceutical company based on technology developed by Hadassah University Medical Center.
Last March, according to the media, it announced an alliance with the Indian pharmaceutical company Premas Biotech in order to develop a new vaccine that It is administered orally, which initially makes it different from all the COVID-19 vaccines on the market, since they are all injected.
Forbes magazine reports that clinical trials They will involve 24 volunteers who will take one or two pills each, and then measure safety and immunity levels, before moving on to the demonstration of efficacy, in a third phase of clinical trials.
The media points out that this vaccine It comes with protection against hitherto known variants of the coronavirus, even more effectively than vaccines on the current market, thanks to the fact that it is based on three viral proteins instead of just one.
The pharmaceutical laboratory also announced that this vaccine in the form of a dragee serves as a booster for those people who have already been vaccinated with its complete schedule (two doses, in the case of Pfizer, Moderna, AstraZeneca and Sputnik, and one, in the case of Janssen).
Once these steps are completed, the manufacturers want to submit their vaccine for approval by the FDA, the health entity in the United States, to sell it in that country.